| Budget Amount *help |
¥24,570,000 (Direct Cost: ¥18,900,000、Indirect Cost: ¥5,670,000)
Fiscal Year 2011: ¥7,930,000 (Direct Cost: ¥6,100,000、Indirect Cost: ¥1,830,000)
Fiscal Year 2010: ¥5,720,000 (Direct Cost: ¥4,400,000、Indirect Cost: ¥1,320,000)
Fiscal Year 2009: ¥10,920,000 (Direct Cost: ¥8,400,000、Indirect Cost: ¥2,520,000)
|
|---|
| Research Abstract |
Using hybridoma library established from rat immunized with canine lymphoma cell line, canine PSGL-1 was found to be expressed on normal lymphocytes, but was specifically glycosylated in lymphoma cell line. This indicated that specifically glycosylated canine PSGL-1 molecule could be a target for antibody therapy. On the other hands, Flavopiridol, known as pan-CDK inhibitor, inhibited growth of eight lymphoma cell lines in vitro by regulation of cell cycle, as well as downregulation of anti-apoptotic proteins. Furthermore, we identified the genes specifically expressed in canine lymphoma, which could be a candidate for molecular target therapy in canine lymphoma.
|
